The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
Lavu CEO Saleem Khatri joins to explain how AI-powered POS systems are changing how major franchises like KFC take orders, cut costs, and serve customers faster
BillionToOne's Jen Hoskovec breaks down the Unity test, the latest in prenatal genetic screening, and what it means for those born with genetic conditions.
Orangetheory Brand President Lauren Cody on the fitness industry's shift from chasing aesthetics to prioritizing longevity and measurable health and wellness.
Peachtree Group CEO Greg Friedman breaks down the Fed's rate decision and the Senate's housing affordability bill and what it means for commercial real estate.
